After weeks of speculation as to whether MannKind would find a marketing partner for its inhalable insulin, the drugmaker said today that Sanofi would acquire global licensing rights to the drug for $925 million.
The painkiller’s marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline
July 9, 2013
8:53 pm
A two-year study shows Gilead’s Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Business briefs: Lundbeck, FDA, Tower Watson and National Business Group Study, Merck
March 7, 2013
5:01 pm
Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn’t sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief
Company news: GSK, Salix
November 8, 2012
9:30 pm
GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013.
Company news: Auxilium and GSK; J&J’s Janssen
May 22, 2012
7:13 pm
Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US.
Company news: WebMD, Wiley-Blackwell and Eli Lilly/Boehringer Ingelheim
March 7, 2012
3:30 pm
WebMD the Magazine is now part of the iPad app world.
Amylin, parting ways with Lilly, plans for extra sales reps
Amylin said it will hire 365 sales reps to make up for Eli Lilly’s departure from commercial activities, once the firm takes full control of the exenatide diabetes franchise in the US this month.
Vertex has succeeded in bringing one heck of a new drug to market in Incivek (in-SEE-veck, or telaprevir), a hepatitis C drug 15 years in the making which promises to cut treatment time in half. Selling the drug against the combined might of Roche and Merck could be nearly as tricky.
